October 2016

 

In this Issue

SFA Intervention: The Next Level

Considerations on tomorrow's effectiveness benchmarks.

Issue

Supplement

European
Supplement

CHIEF MEDICAL EDITORS’ PAGE

SFA Intervention: The Next Level

By John R. Laird, MD; and Fabrizio Fanelli, MD

COVER STORIES

The Future of Femoropopliteal Studies

A discussion on the challenges of applying current trial data and improvements that could guide evidence-based decision making.

By Mehdi H. Shishehbor, DO, MPH, PhD

Ask the Experts: What SFA Trials Would You Most Like to See?

Experts discuss key questions to answer, potential trial designs, and the likelihood that the trials will be undertaken.

With Peter A. Schneider, MD; Thomas Zeller, MD; Osamu Iida, MD; Marianne Brodmann, MD; Krishna Rocha-Singh, MD; and Christopher Metzger, MD

Economic Analysis in Peripheral Artery Disease

Understanding the cost-effectiveness of new devices and treatment strategies.

By Adam C. Salisbury, MD, MSc; and David J. Cohen, MD, MSc

Cost-Effectiveness Analysis of Drug-Eluting Stents and Drug-Coated Balloons

Considerations unique to a single-payor system.

By Konstantinos Katsanos, MSc, MD, PhD, EBIR

Ask the Experts: What Will Dominate the Next Era in SFA Therapy?

Experts discuss the current era of drug-eluting technologies and what might come next.

With Koen Deloose, MD; Craig Walker, MD; and Ramon L. Varcoe, MBBS, MS, FRACS, PhD

The Evolving Role of Preclinical Evaluation in SFA Therapy

Dr. Juan F. Granada discusses the current climate of preclinical research, lessons learned in evaluating drug-eluting technologies, common misconceptions, and what the future holds.

With Juan F. Granada, MD, FACC

Lower Extremity Imaging Wish List: What Capabilities Should We Have By 2021?

A look at the future of lower extremity imaging over the next 5 years.

By Constantino S. Peña, MD

MEDICAL AFFAIRS CORNER

Sponsored by Medtronic

IN.PACT™ Admiral™ Drug-Coated Balloon: The Latest Data

By Peter A. Schneider, MD

FEATURED STUDY

Sponsored by Cardiovascular Systems, Inc.

Promising New 30-Day Data for Lower Extremity Endovascular Treatment

Discussion and roundtable interview of the LIBERTY 360° study of 1,204 Rutherford class 2 to 6 patients, including 100 Rutherford class 6 patients.

By George L. Adams, MD, MHS; Gary M. Ansel, MD; William A. Gray, MD; and J.A. Mustapha, MD

DEPARTMENTS

Innovations

An Interview With Lars Lönn, EBIR, FCIRSE

Prof. Lönn shares his advice on critical aspects of TEVAR procedures, as well as the use of robotics and simulation training in endovascular therapies.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.